PRIMARY SCLEROSING CHOLANGITIS
Clinical trials for PRIMARY SCLEROSING CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY SCLEROSING CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug A3907 tested for rare liver disease, study halted early
Disease control TerminatedThis study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Antibiotic vancomycin tested as PSC treatment – trial stopped early
Disease control TerminatedThis study tested whether the antibiotic vancomycin, taken by mouth, is safe and effective for adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were randomly assigned to receive vancomycin or a placebo. The main goal was to see if van…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2, PHASE3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC